No abstract

Key Points Question Is the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) associated with better outcomes for patients with stage III epithelial ovarian cancer? Findings In this multicenter retrospective cohort study of 584 patients with stage III epithelial ovarian cancer, for patients undergoing PCS with HIPEC and those undergoing PCS alone, the median overall survival was 49.8 and 34.0 months, respectively, and the 3-year overall survival rates were 60.3% and 49.5%, respectively. Complete PCS with HIPEC was associated with the best survival outcomes, with a median overall survival of 53.9 months and a 3-year overall survival rate of 65.9%. Meaning In this study, the addition of HIPEC to PCS was associated with better survival outcomes for patients with stage III epithelial ovarian cancer.

No abstract

No abstract